Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Surg Oncol. 2010 May;17(5):1392-7. doi: 10.1245/s10434-009-0855-0. Epub 2010 Mar 9.

Topoisomerase 2 alpha and the case for individualized breast cancer therapy.

Author information

  • 1Department of Surgery, National University of Ireland, Galway, Clinical Science Institute, Costello Road, Galway, Ireland.

Abstract

BACKGROUND:

Many patients with breast cancer receive no benefit from their treatment. This has led to a search for novel therapeutic targets whose identification may facilitate a more tailored approach, thereby avoiding unnecessary toxicity. Of these, topoisomerase 2 alpha (TOP2A), located at the HER2/neu amplicon on chromosome 17, has generated particular interest because its expression has been shown to correlate with response to anthracycline-based therapies.

METHODS:

We evaluated the relationship between TOP2A and its collocated gene, HER2/neu, and summarized the evidence for and against confining anthracycline-based therapies to those patients who demonstrate increased expression or amplification of these targets.

RESULTS:

The emerging consensus supports the restriction of anthracyclines to those patients who are HER2/neu positive, with the evidence suggesting that alterations in the status of TOP2A are almost completely restricted to this group of patients.

CONCLUSIONS:

It seems increasingly likely that response to anthracyclines is predicated on these alterations.

PMID:
20217261
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk